

# Skin Disease-Oriented Team

---

## Clinical Research Treatment Flowchart

**Clinical Research Manager:**  
Mehir Tharani

**Clinical Research Coordinators:**  
Bao-An Huynh  
Natalie Arechiga  
Erin Palmer-Torrison  
Anastasiia Reipolska

## First Line, Resectable

### SWOG 2015

1cm v 2cm margin

PI: Yamamoto

CRC: N. Arechiga

Accrual: 15/30

## Adjuvant, Stage 2

### UCI 23-220

Pembro vs Biosimilar

PI: Chow

CRC: E. Palmer-Torrison

Accrual: 0/10

**Pending Activation**

## First Line, Stage 3 Neoadjuvant + Adjuvant

### UCI 23-220

Adjuvant Pembro vs

Biosimilar

PI: Chow

CRC: E. Palmer-Torrison

Accrual: 0/10

**Pending Activation**

## First Line, Metastatic or unresectable without previous CPI

### EA6141

(III or IV)

Ipi + Nivo + sargramostin **vs.**

Ipi + Nivo

PI: Chow

CRC: A. Reipolska

Accrual: 4/7

## 2<sup>nd</sup> Line + Metastatic or unresectable

### UCI 24-82

MEK/RAF Inhibitors

(RAS/RAF mutation

NRAS or BRAF class II or III)

PI: Valerin

CRC: C. Kang

Accrual: 1/10

### UCI 22-49

Pembro + Cyclophosphamide

PI: Chow

CRC: B. Huynh

Accrual: 1/14

### UCI 24-112

Vusolimogene Oderparepvec

(HSV-1) + Nivo **vs.**

Physician's Choice

PI: Tran

CRC: A. Reipolska

Accrual: 0/5

Open

Low Accrual

Pending  
Activation  
or  
Suspended

Consider Broad Phase 1 Studies

<div><div><u>UCI 20-67</u></div><div>DF1001 (HER2 NK- engager)</div><div>PI: Valerin</div><div>CRC: M. Nguyen</div><div>Accrual: 18/29</div></div>	<div><div><u>UCI 21-40</u></div><div>DF6002 (IL-12) monotherapy and combo (Nivolumab)</div><div>PI: Valerin</div><div>CRC: B. Huynh</div><div>Accrual: 5/10</div></div>	<div><div><u>UCI 23-197</u></div><div>DF6215 (IL-2)</div><div>PI: Valerin</div><div>CRC: N. Arechiga</div><div>Accrual: 3/5</div><div>Waitlist only</div></div>	<div><div><u>UCI 24-82</u></div><div>MEK/RAF Inhibitors (RAS/RAF mutation NRAS or BRAF class II or III)</div><div>PI: Valerin</div><div>CRC: C. Kang</div><div>Accrual: 1/10</div></div>	<div><div><u>UCI 23-148</u></div><div>CJRB-101 (<i>L. mesenteroides</i>) + Pembro</div><div>PI: Nagasaka</div><div>CRC: J. Choe</div><div>Accrual: 3/6</div><div>Accrual pause until ~July 2025</div></div>	<div>Open</div> <div>Low Accrual</div> <div>Pending Activation or Suspended</div>
--	---	---	--	---	---

Non-interventional Trials

UCI 19-135

DecisionDx-Melanoma Impact on  
Sentinel Lymph Node Biopsy Decisions  
and Clinical Outcomes (DECIDE)

PI: Yamamoto

CRC: Anastasiia R.

Accrual: 84/90

UCI 23-149

Multiphoton Microscopy Imaging as a  
Tool to Monitor Immune Activation  
Induced by Checkpoint Inhibitors

PI: Ganesan

Contact: Hira Rizwi

Accrual: 2/15

UCI 23-93

Assessment of ICOS as a Novel Biomarker  
to Determine Response and Resistance of  
Checkpoint Immunotherapy for Cutaneous  
Malignancies

PI: Tran

CRC: TBD

Target Accrual: 15

Pending Activation

Recurrent

**ETCTN 10592**  
M1774 +/- avelumab  
PI: Gao  
CRC: N. Arechiga  
Accrual: 2/5

Open

Low Accrual

Pending  
Activation  
or  
Suspended

Broad Phase 1 trials

UCI 21-40

DF6002 (IL-12) monotherapy and combo  
(Nivolumab)

PI: Valerin

CRC: B. Huynh

Accrual: 5/10

Non-interventional Trials

UCI 11-30  
(IRB 2008-6307)  
Skin Imaging with Technologies in Development  
PI: Kelly  
Accrual: 636/750

UCI 13-13  
(IRB 2011-8494)  
In-Vivo Non-Invasive Skin Imaging Using  
Multiphoton Microscopy and Multispectral Imaging  
PI: Kelly  
Accrual: 202/250

Interventional Trials

UCI 23-153  
Topical HT-001 for Skin Toxicities w/EGFR Inhib.  
PI: Smith  
CRC: B. Huynh  
Accrual: 2/16

Open

Low Accrual

Pending  
Activation  
or  
Suspended